Struan F. A. Grant

Struan F. A. Grant

Auto-generated profile, based on publicly available information

Struan F. A. Grant

Department of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2006 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SGStruan F A Grant
Struan F A Grant
GTGudmar Thorleifsson
Gudmar Thorleifsson
IRInga Reynisdottir
Inga Reynisdottir
RBRafn Benediktsson
Rafn Benediktsson
AMAndrei Manolescu
Andrei Manolescu
KSKari Stefansson
Kari Stefansson

5 October 2007 in Genome Research
Verified
Journal Article
Open access
PDF file
KWKai Wang
Kai Wang
MLMingyao Li
Mingyao Li
DHDexter Hadley
Dexter Hadley
RLRui Liu
Rui Liu
JGJoseph Glessner
Joseph Glessner
MBMaja Bucan
Maja Bucan
Comprehensive identification and cataloging of copy number variations (CNVs) is required to provide a complete view of human genetic variation. The resolution of CNV detection in previous experimental designs has been limited to tens or hundreds of kilobases. Here we present PennCNV, a hidden Markov model (HMM) based approach, for kilobase-resolution detection of CNVs from Illumina high-density SNP genotyping data. This algorithm incorporates multiple sources of information, including total signal intensity and allelic intensity ratio at each SNP marker, the distance between neighboring SNPs, the allele frequency of SNPs, and the pedigree information where available. We applied PennCNV to genotyping data generated for 112 HapMap individuals; on average, we detected ∼27 CNVs for each individual with a median size of ∼12 kb. Excluding common rearrangements in lymphoblastoid cell lines, the fraction of CNVs in offspring not detected in parents (CNV-NDPs) was 3.3%. Our results demonstrate the feasibility of whole-genome fine-mapping of CNVs via high-density SNP genotyping.

28 April 2009 in Nature
Verified
Journal Article
Open access
PDF file
JGJoseph Glessner
Joseph Glessner
KWKai Wang
Kai Wang
GCGuiqing Cai
Guiqing Cai
OKOlena Korvatska
Olena Korvatska
CKCecilia E. Kim
Cecilia E. Kim
HHHakon Hakonarson
Hakon Hakonarson
Several lines of evidence point to genetic involvement in autism spectrum disorders (ASDs), neurodevelopmental and neuropsychiatric disorders characterized by impaired verbal communication and social interaction. The clinical and genetic complexities of the condition make it difficult to identify susceptibility factors, but two related studies now present robust evidence for a genetic involvement. The first, a genome-wide association study, identifies six single-nucleotide polymorphisms strongly associated with autism. These variants lie between two genes encoding neuronal cell-adhesion molecules (cadherins 9 and 10), suggesting possible involvement in ASD pathogenesis. The second study used copy number variation screens to identify genetic variants in two major gene pathways in children with ASDs. The changes are in the ubiquitin pathway, which has previously been associated with neurological disease, and in genes for neuronal cell-adhesion molecules. Autism spectrum disorders (ASDs) are neurodevelopmental disorders characterized by impairments in social and communication skills. Accumulating evidence suggests a genetic component to ASDs, and here a two-stage, genome-wide approach is used to identify candidate genomic loci enriched in ASD cases. The majority of these loci are found to be involved in neuronal adhesion and ubiquitin degradation, suggesting novel susceptibility mechanisms. Autism spectrum disorders (ASDs) are childhood neurodevelopmental disorders with complex genetic origins1,2,3,4. Previous studies focusing on candidate genes or genomic regions have identified several copy number variations (CNVs) that are associated with an increased risk of ASDs5,6,7,8,9. Here we present the results from a whole-genome CNV study on a cohort of 859 ASD cases and 1,409 healthy children of European ancestry who were genotyped with ∼550,000 single nucleotide polymorphism markers, in an attempt to comprehensively identify CNVs conferring susceptibility to ASDs. Positive findings were evaluated in an independent cohort of 1,336 ASD cases and 1,110 controls of European ancestry. Besides previously reported ASD candidate genes, such as NRXN1 (ref. 10) and CNTN4 (refs 11, 12), several new susceptibility genes encoding neuronal cell-adhesion molecules, including NLGN1 and ASTN2, were enriched with CNVs in ASD cases compared to controls (P = 9.5 × 10-3). Furthermore, CNVs within or surrounding genes involved in the ubiquitin pathways, including UBE3A, PARK2, RFWD2 and FBXO40, were affected by CNVs not observed in controls (P = 3.3 × 10-3). We also identified duplications 55 kilobases upstream of complementary DNA AK123120 (P = 3.6 × 10-6). Although these variants may be individually rare, they target genes involved in neuronal cell-adhesion or ubiquitin degradation, indicating that these two important gene networks expressed within the central nervous system may contribute to the genetic susceptibility of ASD.

28 April 2009 in Nature
Verified
Journal Article
Closed access
PDF file
KWKai Wang
Kai Wang
HZHaitao Zhang
Haitao Zhang
DMDeqiong Ma
Deqiong Ma
MBMaja Bucan
Maja Bucan
JGJoseph Glessner
Joseph Glessner
HHHakon Hakonarson
Hakon Hakonarson

4 January 2021 in Genome Biology
Verified
Journal Article
Open access
PDF file
DCDiana L. Cousminer
Diana L. Cousminer
YWYadav Wagley
Yadav Wagley
JPJames A. Pippin
James A. Pippin
AEAhmed Elhakeem
Ahmed Elhakeem
GWGregory P. Way
Gregory P. Way
SGStruan F. A. Grant
Struan F. A. Grant
Background: Bone accrual impacts lifelong skeletal health, but genetic discovery has been primarily limited to cross-sectional study designs and hampered by uncertainty about target effector genes. Here, we capture this dynamic phenotype by modeling longitudinal bone accrual across 11,000 bone scans in a cohort of healthy children and adolescents, followed by genome-wide association studies (GWAS) and variant-to-gene mapping with functional follow-up.Results: We identify 40 loci, 35 not previously reported, with various degrees of supportive evidence, half residing in topological associated domains harboring known bone genes. Of several loci potentially associated with later-life fracture risk, a candidate SNP lookup provides the most compelling evidence for rs11195210 (SMC3). Variant-to-gene mapping combining ATAC-seq to assay open chromatin with high-resolution promoter-focused Capture C identifies contacts between GWAS loci and nearby gene promoters. siRNA knockdown of gene expression supports the putative effector gene at three specific loci in two osteoblast cell models. Finally, using CRISPR-Cas9 genome editing, we confirm that the immediate genomic region harboring the putative causal SNP influences PRPF38A expression, a location which is predicted to coincide with a set of binding sites for relevant transcription factors.Conclusions: Using a new longitudinal approach, we expand the number of genetic loci putatively associated with pediatric bone gain. Functional follow-up in appropriate cell models finds novel candidate genes impacting bone accrual. Our data also raise the possibility that the cell fate decision between osteogenic and adipogenic lineages is important in normal bone accrual.

8 February 2004 in Nature Genetics
Verified
Journal Article
Open access
PDF file
AHAnna Helgadottir
Anna Helgadottir
AMAndrei Manolescu
Andrei Manolescu
GTGudmar Thorleifsson
Gudmar Thorleifsson
SGSolveig Gretarsdottir
Solveig Gretarsdottir
HJHelga Jonsdottir
Helga Jonsdottir
KSKari Stefansson
Kari Stefansson
We mapped a gene predisposing to myocardial infarction to a locus on chromosome 13q12–13. A four-marker single-nucleotide polymorphism (SNP) haplotype in this locus spanning the gene ALOX5AP encoding 5-lipoxygenase activating protein (FLAP) is associated with a two times greater risk of myocardial infarction in Iceland. This haplotype also confers almost two times greater risk of stroke. Another ALOX5AP haplotype is associated with myocardial infarction in individuals from the UK. Stimulated neutrophils from individuals with myocardial infarction produce more leukotriene B4, a key product in the 5-lipoxygenase pathway, than do neutrophils from controls, and this difference is largely attributed to cells from males who carry the at-risk haplotype. We conclude that variants of ALOX5AP are involved in the pathogenesis of both myocardial infarction and stroke by increasing leukotriene production and inflammation in the arterial wall.